MedTrace Logo

Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers

NCT07285122 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-02-23

No results posted yet for this study

Summary

This is a 3-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled RB042.

Conditions

  • Healthy
  • Healthy Smoker

Interventions

DRUG

RB042

A single or multiple doses of RB042 will be administered via a nebuliser.

DRUG

Placebo inhalation solution

A single or multiple doses of placebo will be administered via a nebuliser.

Sponsors & Collaborators

  • RAGE Bio

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-16
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07285122 on ClinicalTrials.gov